Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2023’, provides an overview of the Esophageal Squamous Cell Carcinoma (ESCC) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Squamous Cell Carcinoma (ESCC) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Esophageal Squamous Cell Carcinoma (ESCC)
- The report reviews pipeline therapeutics for Esophageal Squamous Cell Carcinoma (ESCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Squamous Cell Carcinoma (ESCC) therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Squamous Cell Carcinoma (ESCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Squamous Cell Carcinoma (ESCC)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Squamous Cell Carcinoma (ESCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAbbVie Inc
Adaptimmune Therapeutics Plc
Akeso Inc
Alphamab Oncology
Amgen Inc
Antagen Pharmaceuticals Inc
Antengene Corp Ltd
AP Biosciences Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
BioMed Valley Discoveries Inc
BioNTech SE
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bristol-Myers Squibb Co
Centrymed Pharmaceutical Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
Coherent Biopharma
Coherus BioSciences Inc
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Dyadic International Inc
Eisai Co Ltd
Elpiscience Biopharma Ltd
Ennaid Therapeutics LLC
EpimAb Biotherapeutics Inc
Everest Medicines Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fujian Haixi New Medicine Creation Co Ltd
Genentech USA Inc
Genor BioPharma Co Ltd
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Hangzhou Sumgen Biotech Co Ltd
HEC Pharma Co Ltd
HitGen Inc
Huabo Biopharm (Shanghai) Co Ltd
Huahui Health Ltd
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
ImmuneOncia Therapeutics Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Innovent Biologics Inc
Jacobio Pharmaceuticals Group Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangxi Qingfeng Pharmaceutical Co Ltd
JSR Life Sciences LLC
Keythera Pharmaceuticals Co Ltd
Kintor Pharmaceutical Ltd
Kochi University
Laekna Therapeutics Shanghai Co Ltd
Lee's Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
Lisata Therapeutics Inc
Luye Pharma Group Ltd
Mabpharm Ltd
Merck & Co Inc
Merus NV
Minghui Pharmaceutical (Shanghai) Co Ltd
Molecular Templates Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Novartis AG
Nuvalent Inc
Nuvectis Pharma Inc
OBI Pharma Inc
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pieris Pharmaceuticals Inc
PlantForm Corp
POINT Biopharma Global Inc
Rapa Therapeutics LLC
Salubris Biotherapeutics Inc
Sanofi
Seagen Inc
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Gefeimu Biomedical Technology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Institute of Biological Products Co Ltd
Shanghai JMT-Bio Technology Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
Sichuan University
SinoCelltech Group Ltd
Sorrento Therapeutics Inc
Suzhou Medilink Therapeutics Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Systimmune Inc
TCR Cure Biopharma Technology Co Ltd
The First Affiliated Hospital of Zhengzhou University
Transcenta Holding Ltd
Volastra Therapeutics Inc
Wuxi Biocity Biopharma Co Ltd
Xuanzhu Biotechnology Co Ltd
Yonsei University
Zai Lab Ltd
Zhejiang Pharmaceutical Co Ltd